Q-omics provides the consensus-scored NT5CP1 profile across patient tissues and cancer cell-line models. NT5CP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NT5CP1 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, NT5CP1 RNA expression shows 15,896 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where NT5CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5CP1 survival associations across molecular data types. NT5CP1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5CP1 RNA expression–survival associations across cancer types. High NT5CP1 expression shows unfavorable associations in KIRC, LUSC, LGG, COAD and READ, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify KIRC as the clearest survival context for NT5CP1 RNA expression.
This table summarizes NT5CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NT5CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5CP1 shows lower tumor expression in LUSC, THCA and LUAD and higher tumor expression in KICH and LIHC. The KICH box plot shows higher NT5CP1 RNA expression in tumor versus normal tissue (log2 FC = +0.343, t-test p < 0.001).
This table shows molecular features associated with NT5CP1 in patient tissues and cancer cell lines. In patient samples, NT5CP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
